Human pluripotent stem cells (hPSCs) are a powerful tool for studying human development and disease and for applications in regenerative medicine. The use of hPSCs differentiated towards central nervous system lineages has been of particular interest given the lack of effective therapies for many neurodegenerative and neuropsychiatric disorders and the availability of protocols to efficiently direct neuronal specification in vitro (Chambers et al., 2009). Early studies using hPSCs have been primarily geared towards neurodegenerative disorders, which are known to affect specific neuron types such as midbrain dopamine neurons in Parkinson’s disease (PD; (Kriks et al., 2011)) or motor neurons in amyotrophic lateral sclerosis (ALS; (Dimos et al., 2008)) and spinal muscular atrophy (SMA; (Ebert et al., 2009)). More recent studies suggest the possibility of tackling complex neuronal disorders such as Schizophrenia (Brennand et al., 2011) or autism-related syndromes (Marchetto et al., 2010; Pasca et al., 2011). Unlike in PD, ALS or SMA, the neuron types critical for modeling schizophrenia or autism are less well defined, and no attempts have been made to direct neuron subtype identity in those studies. There
